JAKARTA. In the bustling Indonesian stock market, companies (issuers) are increasingly turning to capital-raising strategies like private placements and rights issues. This surge in corporate actions necessitates careful consideration from investors, who must keenly scrutinize these maneuvers before committing their capital.
One recent example is PT Diagnos Laboratorium Utama Tbk (DGNS), which successfully raised fresh capital amounting to Rp 7.97 billion through a private placement. This corporate action, formally known as a Capital Increase Without Pre-emptive Rights (PMTHMETD), saw DGNS issue 29.65 million new shares at a price of Rp 269 per share. Notably, the entirety of these new shares was acquired by Gene Richard, an individual investor with no affiliation to the company.
Stefanus Ivanly, VP Corporate Secretary of DGNS, stated on Friday (May 8, 2026), that the proceeds from this private placement are earmarked for the company’s business development. This includes bolstering working capital, expanding its network of outlets, purchasing shares and assets, or acquiring equity stakes in one or more companies within industries relevant to the group’s operations.
The trend extends beyond DGNS. PT Merdeka Copper Gold Tbk (MDKA), for instance, has also announced plans for a private placement of up to 2.44 billion shares, representing 10% of its total issued and fully paid shares. MDKA intends to utilize the funds raised from this private placement to support its working capital requirements and fuel the business development initiatives of both the company and its group entities.
Similarly, PT Equity Development Investment Tbk (GSMF) is gearing up for a private placement, aiming to issue a maximum of 1.4 billion new Series C shares at a nominal value of Rp 100 per share. GSMF plans to deploy these funds to accelerate business development, fortify its capital structure, and ensure the smooth execution of operations for both the company and its subsidiaries. Additionally, PT Bank Ina Perdana Tbk (BINA), PT Global Digital Niaga Tbk (BELI), and PT Sarana Meditama Metropolitan Tbk (SAME) all announced their own private placement agendas towards the end of April 2026.
Beyond private placements, a number of issuers have also unveiled plans for rights issues, or Capital Increases with Pre-emptive Rights (PMHMETD). PT Energi Mega Persada Tbk (ENRG), for example, intends to issue approximately 13.5 billion new Series B shares through a rights issue at a nominal value of Rp 100 per share. The capital generated from this corporate action will be channeled into supporting capital expenditures and meeting working capital needs for both ENRG and its subsidiaries.
Another Bakrie Group issuer, PT VKTR Teknologi Mobilitas Tbk (VKTR), is also set to conduct a rights issue, planning to issue 25 billion new shares. The funds secured from this offering will be allocated towards additional working capital and equity participation in its subsidiaries. Furthermore, PT Pyridam Farma Tbk (PYFA) is preparing for its second rights issue, involving the issuance of 5.7 billion new shares alongside up to 3.8 billion warrants. The proceeds from PYFA’s rights issue are earmarked for strengthening its capital structure and acquiring the Mayne Pharma plant located in South Australia.
Ekky Topan, an Investment Analyst at Infovesta Utama, observes that the busy trend of private placements and rights issues since April 2026 clearly indicates a significant ongoing demand for funding among issuers. He clarifies that the underlying purpose of these corporate actions is not always purely expansionary. Funds are also frequently utilized to bolster capital structures, provide working capital, facilitate acquisitions, and improve balance sheets.
The prevalence of these capital-raising activities also suggests that, despite prevailing market volatility, liquidity remains available in the stock market, albeit selectively. Topan emphasizes that investors are more likely to participate in corporate actions when business prospects are clear, fund utilization is productive, the execution price is appealing, and there is robust support from major shareholders or strategic investors.
Furthermore, Topan explains that a private placement can serve as a swift method for issuers to secure funds while simultaneously opening doors for strategic investors. A rights issue, on the other hand, provides existing shareholders with the opportunity to maintain their ownership percentage in the company.
Despite these advantages, the potential for share dilution remains a critical concern for investors. A private placement can reduce the ownership stake of existing investors since not all shareholders are eligible to participate. Similarly, a rights issue carries the risk of dilution if shareholders choose not to exercise their pre-emptive rights to subscribe to new shares. For instance, MDKA’s private placement could lead to a dilution of approximately 9.09% for shareholders. The dilution impact from VKTR’s and PYFA’s rights issues is projected to be even higher, at 36.36% and 45.69% respectively.
Harry Su, Managing Director of Research at Samuel Sekuritas Indonesia, highlights that if a private placement or rights issue is not optimally executed, it can lead to a valuation derating. This occurs when an increased number of outstanding shares results in a potential decrease in the share price of the issuing company. Conversely, Su notes that if an issuer demonstrates agility in deploying the funds raised from a private placement or rights issue, both its performance and share price can rise, even with a larger number of shares in circulation.
Su projects that a continued improvement in stock market conditions and a clearer trajectory for the exchange’s transformation will likely encourage even more private placements and rights issues. He adds that issuers best positioned to maximize the benefits of a rights issue are those that dedicate the funds to expansionary activities. Nevertheless, the ultimate success of these corporate actions hinges on prevailing market conditions, the execution price, the business’s prospects, and the unwavering commitment of major shareholders.
Ekky Topan strongly advises investors against immediately viewing private placements or rights issues as positive sentiment indicators. Instead, investors must diligently examine the intended use of funds, the extent of potential dilution, the execution price, the company’s fundamental health, and the background of the parties subscribing to the new shares. If a corporate action is poised to strengthen the balance sheet and foster profit growth, then any ensuing share price correction could present an attractive accumulation opportunity for savvy investors. However, Topan cautions that “if the dilution is substantial and the business prospects remain unclear, it’s prudent to exercise greater caution.”
Among the various issuers planning private placements and rights issues, Harry Su recommends a “buy” rating for ENRG shares, setting a target price of Rp 2,300 per share.
Summary
Indonesian issuers are increasingly utilizing private placements and rights issues to raise capital for business expansion, debt reduction, and working capital needs. Notable companies such as PT Diagnos Laboratorium Utama Tbk, PT Merdeka Copper Gold Tbk, and PT Energi Mega Persada Tbk have initiated these corporate actions to strengthen their balance sheets and support strategic growth. While these maneuvers demonstrate market liquidity, they also present risks of share dilution for existing investors, necessitating careful scrutiny of how the raised funds are deployed.
Analysts advise investors to look beyond the immediate announcement and evaluate the fundamental health of the issuing company, the transparency of fund usage, and the potential impact of share dilution. While well-executed capital raisings that fuel productive growth can enhance long-term performance, poor execution may lead to valuation derating and decreased share prices. Ultimately, investors should treat these corporate actions as complex events that require a thorough assessment of business prospects and major shareholder commitment before making investment decisions.